Traws Pharma Framtida tillväxt

Future kriterier kontrolleras 2/6

Traws Pharma förväntas öka vinsten och intäkterna med 45.5% och 56.3% per år respektive medan EPS förväntas växa med 48.5% per år.

Viktig information

45.5%

Tillväxttakt i vinsten

48.47%

Tillväxttakt för EPS

Pharmaceuticals vinsttillväxt	14.5%
Intäkternas tillväxttakt	56.3%
Framtida avkastning på eget kapital	n/a
Bevakning av analytiker	Low
Senast uppdaterad	20 May 2026

Senaste uppdateringarna om framtida tillväxt

Recent updates

Ny berättelse • Apr 30

Pandemic Preparedness And Once Monthly Oral Flu Prophylaxis Will Transform This Antiviral Opportunity

Catalysts About Traws Pharma Traws Pharma is a biotechnology company focused on developing next generation antiviral treatments and prophylactic agents for influenza. What are the underlying business or industry changes driving this perspective?

Ny berättelse • Apr 16

Regulatory And Funding Risks Around Influenza Catalyst Will Eventually Support A Healthier Outlook

Catalysts About Traws Pharma Traws Pharma is a clinical stage company focused on developing next generation antiviral treatments and prophylactic therapies for influenza. What are the underlying business or industry changes driving this perspective?

Analysartikel • Mar 09

We're Keeping An Eye On Onconova Therapeutics' (NASDAQ:ONTX) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analysartikel • Apr 22

Here's Why We're Watching Onconova Therapeutics' (NASDAQ:ONTX) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Analysartikel • Jul 27

Onconova Therapeutics (NASDAQ:ONTX) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Analysartikel • Mar 21

Will Onconova Therapeutics (NASDAQ:ONTX) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Analysartikel • Dec 06

Companies Like Onconova Therapeutics (NASDAQ:ONTX) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Prognoser för vinst- och omsättningstillväxt

NasdaqCM:TRAW - Analytikernas framtida uppskattningar och tidigare finansiella data (USD Millions )
Datum	Intäkter	Intäkter	Fritt kassaflöde	Kassaflöde från rörelsen	Genomsnittligt Antal analytiker
12/31/2028	55	-6	-48	-10	1
12/31/2027	13	-44	-52	-29	2
12/31/2026	N/A	-37	-43	-31	2
3/31/2026	3	-14	-18	-15	N/A
12/31/2025	3	7	-21	-18	N/A
9/30/2025	3	-9	-22	-19	N/A
6/30/2025	3	-5	-27	-27	N/A
3/31/2025	0	-26	-31	-31	N/A
12/31/2024	0	-55	-30	-30	N/A
9/30/2024	0	-37	-30	-30	N/A
6/30/2024	0	-41	-23	-23	N/A
3/31/2024	0	-27	-18	-18	N/A
12/31/2023	0	-19	-18	-18	N/A
9/30/2023	0	-20	-17	-17	N/A
6/30/2023	0	-21	-17	-17	N/A
3/31/2023	0	-21	-17	-17	N/A
12/31/2022	0	-19	-16	-16	N/A
9/30/2022	0	-17	-17	-17	N/A
6/30/2022	0	-15	-17	-17	N/A
3/31/2022	0	-16	-17	-17	N/A
12/31/2021	0	-16	-19	-19	N/A
9/30/2021	0	-19	-21	-21	N/A
6/30/2021	0	-22	-22	-22	N/A
3/31/2021	0	-25	-23	-23	N/A
12/31/2020	0	-25	-23	-23	N/A
9/30/2020	0	-24	-23	-23	N/A
6/30/2020	0	-23	-21	-21	N/A
3/31/2020	2	-19	-21	-21	N/A
12/31/2019	2	-22	N/A	-21	N/A
9/30/2019	2	-21	N/A	-21	N/A
6/30/2019	2	-22	N/A	-24	N/A
3/31/2019	1	-23	N/A	-24	N/A
12/31/2018	1	-21	N/A	-23	N/A
9/30/2018	1	-21	N/A	-22	N/A
6/30/2018	1	-23	N/A	-22	N/A
3/31/2018	1	-21	N/A	-23	N/A
12/31/2017	1	-24	N/A	-24	N/A
9/30/2017	1	-23	N/A	-24	N/A
6/30/2017	2	-18	N/A	-19	N/A
3/31/2017	4	-21	N/A	-17	N/A
12/31/2016	6	-20	N/A	-16	N/A
9/30/2016	15	-11	N/A	-16	N/A
6/30/2016	15	-15	N/A	-22	N/A
3/31/2016	13	-19	N/A	-26	N/A
12/31/2015	11	-24	N/A	-31	N/A
9/30/2015	2	-41	N/A	-40	N/A
6/30/2015	0	-50	N/A	-46	N/A

Analytiker Framtid Tillväxt Prognoser

Intäkter kontra sparande: TRAW förväntas förbli olönsam under de kommande 3 åren.

Resultat vs marknad: TRAW förväntas förbli olönsam under de kommande 3 åren.

Höga tillväxtresultat: TRAW förväntas förbli olönsam under de kommande 3 åren.

Intäkt vs marknad: TRAW s intäkter ( 56.3% per år) förväntas växa snabbare än US marknaden ( 11.7% per år).

Hög tillväxtintäkter: TRAW s intäkter ( 56.3% per år) förutspås växa snabbare än 20% per år.

Tillväxtprognoser för vinst per aktie

Framtida avkastning på eget kapital

Framtida ROE: Otillräcklig data för att avgöra om TRAW s avkastning på eget kapital förväntas bli hög om tre år

Upptäck tillväxtföretag

Företagsanalys och finansiella data Status

Uppgifter	Senast uppdaterad (UTC-tid)
Analys av företag	2026/05/26 20:04
Aktiekurs vid dagens slut	2026/05/22 00:00
Intäkter	2026/03/31
Årlig intjäning	2025/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

Paket	Uppgifter	Tidsram	Exempel US-källa
Företagets finansiella ställning	10 år	Resultaträkning Kassaflödesanalys Balansräkning	SEC Form 10-K SEC Form 10-Q
Analytikernas konsensusuppskattningar	+3 år	Prognos för finansiella poster Analytikernas prismål	Rapporter från analytiker Blue Matrix
Marknadspriser	30 år	Aktiekurser Utdelningar, splittar och åtgärder	ICE Marknadsdata SEC Form S-1
Ägarskap	10 år	Största aktieägare Insiderhandel	SEC Formulär 4 SEC Formulär 13D
Förvaltning	10 år	Ledningsgrupp Styrelse och verkställande direktörer	SEC Form 10-K SEC Form DEF 14A
Viktiga utvecklingstendenser	10 år	Företagsmeddelanden	SEC Formulär 8-K

^* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Traws Pharma, Inc. bevakas av 10 analytiker. 2 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

Analytiker	Institution
Kimberly Lee	Brean Capital Historical (Janney Montgomery)
Michael Thomas Cooper	Edison Investment Research
Etzer Darout	Guggenheim Securities, LLC

Traws Pharma Framtida tillväxt

Future kriterier kontrolleras 2/6

Viktig information

Senaste uppdateringarna om framtida tillväxt

Price target decreased by 22% to US$6.50

Consensus revenue estimates decrease by 19%, EPS upgraded

Consensus EPS estimates upgraded to US$0.97 loss

Consensus revenue estimates fall by 13%

Consensus forecasts updated

Price target decreased to US$8.67

Recent updates

Pandemic Preparedness And Once Monthly Oral Flu Prophylaxis Will Transform This Antiviral Opportunity

Traws Pharma, Inc. announced that it expects to receive $10 million in funding from Sirenia Capital Management LP

Regulatory And Funding Risks Around Influenza Catalyst Will Eventually Support A Healthier Outlook

Traws Pharma, Inc. announced delayed annual 10-K filing

Traws Pharma, Inc. Completes Analysis of Ratutrelvir Clinical Study in Paxlovid-Eligible and Ineligible Covid-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as A Prophylactic Treatment for Seasonal Influenza

Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza

Traws Pharma Files Tivoxavir Marboxil Investigational New Drug Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in Paxlovid-19 Patients

Traws Pharma, Inc. Reports Positive Interim Clinical Data with Ratutrelvir Versus Paxlovid™?, Shows Activity in Paxlovid-Ineligible COVID-19 Patients

Expert Systems Inc. Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir

Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025

Traws Pharma, Inc., Annual General Meeting, Nov 21, 2025

Traws Pharma, Inc. Appoints John Leaman to Its Board of Directors as an Independent Director, Effective October 1, 2025

Traws Pharma, Inc. Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025

Traws Pharma, Inc. to Report Q2, 2025 Results on Aug 14, 2025

Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions

Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness

Traws Pharma, Inc. Announces CEO Changes

Traws Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $5.5142 million.

Traws Pharma Reports Positive Results from an Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil

Traws Pharma Regains Compliance with Nasdaq Minimum Stockholders’ Equity Requirement

Traws Pharma Inc. Announces CFO Changes

Traws Pharma Announces Completion of Phase I Studies with Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird Flu

Expert Systems and Traws Pharma Report Breakthrough in H5N1Bird Flu Antiviral Program

Traws Pharma, Inc. announced that it expects to receive $72.6 million in funding

Traws Pharma, Inc. Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu

Traws Pharma Receives Non-Compliance Letter from Nasdaq Regarding Non-Compliance with the Minimum $2.5 Million Stockholders’ Equity Requirement under Nasdaq Listing Rule 5550(b)(1)

Traws Pharma, Inc., Annual General Meeting, Oct 31, 2024

Traws Pharma, Inc. Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil

Traws Pharma, Inc. Announces Positive Topline Phase 1 Results for Covid Candidate, Ratutrelvir, an Oral Mpro Inhibitor

Nasdaq Determines to Delist Traws Pharma's Securities

Traws Pharma, Inc. Announces Board Changes

Traws Pharma Receives Letter from The Nasdaq Capital Market Due to Non-Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on the Nasdaq Capital Market

Traws Pharma, Inc. announced delayed 10-Q filing

Traws Pharma, Inc. to Report Q2, 2024 Results on Aug 15, 2024

Price target decreased by 22% to US$6.50

New minor risk - Shareholder dilution

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy

High number of new directors

Consensus revenue estimates decrease by 19%, EPS upgraded

Traws Pharma, Inc. Announces Chief Executive Office Changes

Traws Pharma, Inc. Announces Board Changes

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Onconova Therapeutics, Inc and Trawsfynydd Therapeutics, Inc. Announce Management Appointments for the Combined Company Traws Pharma, Inc

We're Keeping An Eye On Onconova Therapeutics' (NASDAQ:ONTX) Cash Burn Rate

Onconova TherapeuticsNarazaciclib Ash Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphoma

Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s

Consensus EPS estimates upgraded to US$0.97 loss

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Onconova Therapeutics, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Onconova Therapeutics, Inc. Appoints Victor Moyo as Chief Medical Officer

Onconova Therapeutics Receives A Letter from the Nasdaq Capital Market Regarding Minimum Bid Price Requirement

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Onconova Therapeutics, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Onconova Therapeutics, Inc. Presents Preclinical Data on Narazaciclib at the 17Th International Conference on Malignant Lymphoma

Onconova Therapeutics, Inc., Annual General Meeting, Jul 21, 2023

Onconova Therapeutics Announces Dosing of First Participant in Investigator-Sponsored Phase 2 Trial of Rigosertib Plus Pembrolizumab in Metastatic Melanoma Patients Refractory to Immune Checkpoint Blockade

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Onconova Therapeutics Doses First Patient in Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial Cancer

Onconova Therapeutics, Inc. to Report Q1, 2023 Results on May 15, 2023

Here's Why We're Watching Onconova Therapeutics' (NASDAQ:ONTX) Cash Burn Situation

Consensus revenue estimates fall by 13%

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Onconova Therapeutics, Inc. Announces Additional Clinical Data Demonstrating Rigosertib’s Monotherapy Activity in RDEB-Associated Squamous Cell Carcinoma

Insufficient new directors

Consensus forecasts updated

Price target decreased to US$8.67

Second quarter 2022 earnings: EPS exceeds analyst expectations

Onconova Therapeutics (NASDAQ:ONTX) Is In A Good Position To Deliver On Growth Plans